Concise drug review: azacitidine and decitabine
EJB Derissen, JH Beijnen, JHM Schellens - The oncologist, 2013 - academic.oup.com
EJB Derissen, JH Beijnen, JHM Schellens
The oncologist, 2013•academic.oup.comThe introduction of the hypomethylating agents azacitidine and decitabine has been a major
advancement in the treatment of patients with higher‐risk myelodysplastic syndromes,
chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more
intensive treatments. This concise drug review summarizes the current state of treatment
with azacitidine and decitabine.
advancement in the treatment of patients with higher‐risk myelodysplastic syndromes,
chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more
intensive treatments. This concise drug review summarizes the current state of treatment
with azacitidine and decitabine.
The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher‐risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.
Oxford University Press